Image: The CardioDefender Diagnostic System (Photo courtesy of Everist Genomics).
An innovative smartphone electrocardiogram (ECG) system provides physicians and patients with hospital-quality heart rhythm monitoring outside of the hospital setting.
The CardioDefender Diagnostic System delivers mobile heart monitoring and automated reporting by combining patented analytical smartphone software with a Bluetooth device and electrodes, enabling the smartphone to perform as a mobile ECG. Among the features of the system are real-time, heart-rhythm monitoring, with beat-by-beat analysis; long term monitoring for up to three months of real-time, beat-by-beat quantitative patient monitoring; and a comprehensive range of heart rhythm monitoring algorithms that enable automated detection and reporting of medically important symptomatic and asymptomatic arrhythmias.
The abnormal heart rhythms are reported directly to the physician, using innovative software and data compression technology to report real-time results to a smartphone, tablets, laptop, or desktop computer, in addition to a cardiac monitoring center. Access is available on demand to full, detailed ECG data captured during the monitoring period, including post heart monitoring data processing for additional measurements. The CardioDefender Diagnostic System is a product of Everist Genomics (Ann Arbor, MI, USA), and has been approved by the US Food and Drug Administration (FDA).
“Physicians who diagnose and treat heart arrhythmias have been hampered for many years by legacy technology, such as hospital based ECG systems which confine patients to the high-cost hospital setting and Holter monitors which do not provide the comprehensive monitoring needed to detect potentially life threatening arrhythmias,” said Alex Charlton, executive vice chairman of Everist Genomics. “For the first time, CardioDefender enables smartphone-based hospital-quality ECG monitoring of patients 24 hours per day, seven days per week.”
In addition to the CardioDefender diagnostic system, the company has recently announced the development of the AngioDefender, a tablet computer device capable of accurately diagnosing atherosclerosis in asymptomatic patients.